Lionco Pharmaceutical Group Co.,Ltd. (SHA:603669)

Market Cap	3.68B
Revenue (ttm)	353.04M
Net Income (ttm)	-133.34M
Shares Out	703.54M
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,336,424
Average Volume	13,330,422
Open	5.01
Previous Close	5.01
Day's Range	5.01 - 5.38
52-Week Range	3.45 - 9.54
Beta	0.57
RSI	62.80
Earnings Date	Aug 28, 2025

About SHA:603669

Lionco Pharmaceutical Group Co., Ltd., together with its subsidiaries, research and development, production, sales and medical services in China. The company offers nutrition, antimicrobial, antiviral, digestion, cardiovascular, detoxification, anti-tumor, and other products. Its project under research covers major disease areas such as anti-tumor, liver disease, and cerebrovascular drugs. The company was founded in 2003 and is based in Shannan, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2003
• Employees: 436
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603669

Financial Performance

In 2024, SHA:603669's revenue was 379.78 million, an increase of 92.95% compared to the previous year's 196.83 million. Losses were -130.76 million, -13.68% less than in 2023.